CYCLONE 2: Abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer
Abemaciclib is an oral selective inhibitor of CDK4&6, that is FDA-approved to treat patients suffering from HR+, HER2- metastatic breast cancer. Recent preclinical studies on prostate cancer cell lines and xenograft models indicate that abemaciclib induces cell cycle arrest and tumor growth inhibition. In this MEDtalk, Redas Trepiakas, MD, presents the results of CYCLONE 2, a randomized, placebo-controlled study investigating the effects of treating metastatic castration-resistant prostate cancer with abiraterone plus prednisone with or without abemaciclib.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.